Ellen Rohde

Ellen Rohde is the current VP of Pharmacology & Toxicology at Verve Therapeutics. Prior to this, they were the Senior Director of Biodistribution & Pharmacokinetics at Intellia Therapeutics where they explored the PK/PD and biodistribution of gene editing therapeutics based on Crispr/Cas9 mechanisms. Ellen has also worked as the Director of Analytical Chemistry & DMPK at Cerulean Pharma, Inc and as a consultant at admetconsult_e. Ellen has a passion for studying disposition (metabolism and elimination) of components of lipid nanoparticles, AAV, gRNA, mRNA and measuring and correlating absolute quantities of lipids, RNAs and proteins with effect over time. Ellen is also experienced in modeling PK/PD relationships of gene editing and subsequent protein changes as well as identifying and optimizing LNPs and RNAs and advancing them towards INDs and FIH studies. Ellen is a strong leader, having led a team of 7 scientists with in vivo pharmacology, bioanalytical, modeling & simulation and biomarker expertise. Ellen has also built infrastructure, teams and CRO collaborations in support of Crispr/Cas9 gene editing with annual budgets exceeding $1.5M.

Ellen Rohde received their PhD in Analytical Chemistry from the University of Cincinnati and then went on to complete a postdoc in biological mass spectrometry at the Mayo Clinic School of Medicine. Ellen also holds a Diplomchemikerin degree in Theoretical and Physical Chemistry from Leipzig University, and their research interests include analytical electrochemistry and electrochemical detection methods.

Ellen Rohde reports to Andrew Bellinger, Chief Scientific Officer & Chief Medical Officer. Some of their coworkers include Jeong-Ah Kwon - Scientist, RNA Analytics, Sara Garcia - Associate Principal Scientist, Computational Biology, and Christos Miliotis - Scientist, Editor Development. Some direct reports include Maurine Braun - Associate Director, Toxicology, Bryan Macdonald - Director, Pharmacology & Toxicology.